Fluicell Signs Second Distribution Agreement for BioPen System in China

Fluicell AB (publ), a single-cell instrumentation company within life science, today announced a new agreement with Premedical Laboratories for the sale and distribution of Fluicell’s BioPen Systems on the Chinese market. This non-exclusive distribution agreement is the company’s second in China, and effective immediately, increases the availability of the Biopen to a broader group of researchers in the rapidly growing life-science space in China.

The non-exclusive distribution agreement with Premedical Laboratories Inc., one of the larger distributors of professional laboratory product solutions within life science in China, was signed on 1st June 2018 and immediately comes into effect. Headquartered in Beijing, the distributor further has a presence in the key industry areas Shanghai, Guangzhou and Wuhan.

“We are pleased to close this deal with a new partner in China. This is our second distributor in China, which certainly opens new doors by increased visibility and reach within the country. We started discussions during an industry conference we participated in earlier this year, and we managed to get a quick closure. We are now looking forward to a productive cooperation with Premedical Laboratories,” said Victoire Viannay, CEO at Fluicell.

The BioPen System is a solution delivery platform that enable researchers to perform localized drug delivery in very small doses to single-cells and tissues. It comprises the two products BioPen PRIME and BioPen FLEX, which are developed to suit the two most common types of microscope within laboratory research. Both products are tailored to enable cost-effective drug development and medical research, primarily targeting academia, research laboratories as well as pharmaceutical and biotech companies.

“As a provider of total laboratory solutions in China, we are devoted to offer innovative research tools in the life science field. That is why we approached Fluicell, we were impressed by their transformative product portfolio and are very happy to enter this agreement with them,” said Guangwei Fan, CEO at Premedical Laboratories.

Fluicell products are currently available in more than 15 countries around the world through a network of distributors. The company is looking at expanding its distribution in strategic markets and are continuously evaluating promising distribution partners that share Fluicell’s values and vision.